Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.

Nature communications - 22 Apr 2021

Wang Zhiyong, Goto Yusuke, Allevato Michael M, Wu Victoria H, Saddawi-Konefka Robert, Gilardi Mara, Alvarado Diego, Yung Bryan S, O'Farrell Aoife, Molinolo Alfredo A, Duvvuri Umamaheswar, Grandis Jennifer R, Califano Joseph A, Cohen Ezra E W, Gutkind J Silvio

Abstract excerpt

Immune checkpoint blockade (ICB) therapy has revolutionized head and neck squamous cell carcinoma (HNSCC) treatment, but <20% of patients achieve durable responses. Persistent activation of the PI3K/AKT/mTOR signaling circuitry represents a key oncogenic driver in HNSCC; however, the potential immunosuppressive effects of PI3K/AKT/mTOR inhibitors may limit the benefit of their combination with ICB. Here we employ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Receptor, ErbB-3

Share to Squamous Cell Carcinoma of Head and Neck

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33888713
DOI: 10.1038/s41467-021-22619-w
PMCID: PMC8062674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.PMID 33888713Read ↗

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular TargetsSemantic proximity Read ↗

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Semantic proximity Read ↗

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)Semantic proximity Read ↗

The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapiesSemantic proximity Read ↗

Impact of PI3K pathway alterations on response to immune checkpoint inhibitors in HPV-negative head and neck squamous cell carcinomaSemantic proximity Read ↗

Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.Semantic proximity Read ↗

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Semantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell CarcinomasSemantic proximity Read ↗

The Determinants of Head and Neck Cancer: Unmasking the PI3K Pathway MutationsSemantic proximity Read ↗

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapySemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.